The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
By cutting pain crises & boosting haemoglobin
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The trial tested six injectable doses and three oral doses over as long as 36 weeks
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Oral semaglutide 25 mg was associated with the same weight loss efficacy in women with obesity regardless of menopausal stage, and patients reported improvements in physical function, respectively
Zaltenibart offers best-in-class potential across multiple rare blood and kidney disorders, enhancing Novo Nordisk’s rare disease portfolio
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Subscribe To Our Newsletter & Stay Updated
